View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
July 5, 2018

Cannabics completes trial of Cannabics SR for CACS

Cannabics Pharmaceuticals has concluded a clinical trial that evaluated Cannabics SR 5mg to treat cancer anorexia-cachexia syndrome (CACS) and advanced forms of the disease.

Cannabics Pharmaceuticals has concluded a clinical trial that evaluated Cannabics SR 5mg to treat cancer anorexia-cachexia syndrome (CACS) and advanced forms of the disease.

The open-label, single group assignment enrolled a total of 24 subjects.

The trial was conducted at Rambam Medical Center (MC) in Israel. European Society for Medical Oncology (ESMO) has recognised Rambam MC’s Oncology Center as a designated Center of Integrated Oncology and Palliative Care.

Rambam MC division of oncology deputy director Gil Bar-Sela is the principal investigator of the trial, which was launched in 2016.

During the trial, patients were treated with Cannabics SR 5mg daily for three months.

“We are awaiting the results and expect them to further elucidate an important aspect of our mission in integrating cannabinoid-based therapies into the world of precision medicine.”

The trial’s primary endpoint was weight gain of ≥10% from baseline. Its secondary endpoints comprised improvement in appetite, nutritional intake, reduction in tumor necrosis factor (TNF) alpha, quality of life (QOL) and others.

According to Cannabics, Rambam MC is currently analysing the official results of the trial and expects to publish the same over the next few months.

Cannabics Pharmaceuticals chief technical officer Eyal Ballan said: “We are awaiting the results and expect them to further elucidate an important aspect of our mission in integrating cannabinoid-based therapies into the world of precision medicine; while at the same time focusing our efforts on bringing scientific data to support developments of cannabinoid-based therapies.”

Headquartered in the US, Cannabics is primarily involved in the development of cannabinoid-based medicine and treatments focused on cancer and its side-effects.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU